论文部分内容阅读
目的 :了解恶性淋巴瘤患者阿霉素血药浓度和药代动力学特点及其临床意义。方法 :2 6例恶性淋巴瘤患者均采用CHOP方案化疗。血药浓度测定用HPLC法。结果 :化疗有效 (CR +PR) 18例 ( 6 9.2 % ) ,无效 8例( 30 .8% )。化疗有效组与无效组的平均血药峰浓度分别为 196 5 .3ng·ml-1和 1177.8ng·ml-1,K12 分别为 2 .6 2 1h-1和 1.76 1h-1,Vc分别为 5 2 6L·m-2 和 8.34L·m-2 ,差异均具有显著性 (P <0 .0 5 )。不同个体间血药浓度和药代动力学差异很大 ,变异系数 36 .5 %～ 75 .8%。结论 :恶性淋巴瘤患者阿霉素血药浓度测定及药代参数分析对预测疗效 ,实行个体化给药方案有一定的临床指导意义
Objective: To know the doxorubicin plasma concentration and pharmacokinetics in patients with malignant lymphoma and its clinical significance. Methods: Twenty-six patients with malignant lymphoma were treated with CHOP chemotherapy. Blood concentration was determined by HPLC method. Results: Chemotherapy was effective (CR + PR) in 18 cases (62.9%) and ineffective in 8 cases (30.8%). The average peak plasma concentrations of chemotherapy-active and non-effective chemotherapy were 196 5 .3 ng · ml-1 and 1177.8 ng · ml-1, respectively. K12 was 2.62-1 h -1 and 1.76 1 h-1, respectively, and Vc was 5 2 6L · m-2 and 8.34L · m-2, the difference was significant (P <0.05). Different individual plasma concentrations and pharmacokinetics vary greatly, the coefficient of variation of 36.5% ~ 75.8%. Conclusion: The determination of doxorubicin in patients with malignant lymphoma and the analysis of pharmacokinetic parameters have some clinical significance in predicting the curative effect and implementing individualized dosing regimen